HRTX (Heron Therapeutics, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by HRTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Mark Earl Hensley | Chief Operating Officer | MIXED | — | — |
| 2026-08-03 | Mark Earl Hensley | Chief Operating Officer | M | — | — |
| 2026-08-03 | Ira Duarte | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-08-03 | William P Forbes | EVP, Chief Development Officer | MIXED | — | — |
| 2026-08-03 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-07-20 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-07-20 | William P Forbes | EVP, Chief Development Officer | MIXED | — | — |
| 2026-07-20 | Ira Duarte | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-06-17 | Ira Duarte | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-06-08 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2026-05-07 | Mark Earl Hensley | Chief Operating Officer | M | — | — |
| 2026-05-04 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2026-05-04 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-05-04 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2026-05-04 | Mark Earl Hensley | Chief Operating Officer | M | — | — |
| 2026-04-21 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-04-21 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2026-04-21 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2026-04-06 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-02-03 | Thomas Cusack | Director | A | — | — |
| 2026-02-03 | Sharmila Dissanaike | Director | A | — | — |
| 2026-02-03 | Waage Christian | Director | A | — | — |
| 2026-02-03 | Michael Kaseta | Director | A | — | — |
| 2026-02-03 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2026-02-03 | Ira Duarte | EVP, Chief Financial Officer | A | — | — |
| 2026-02-03 | Craig A Collard | Chief Executive Officer | A | — | — |
| 2026-02-03 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2026-02-03 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2026-02-03 | Craig A Johnson | Director | A | — | — |
| 2026-02-03 | Adam Morgan | Director | A | — | — |
| 2026-02-03 | William P Forbes | EVP, Chief Development Officer | A | — | — |
| 2026-02-03 | Mark Earl Hensley | Chief Operating Officer | A | — | — |
| 2026-01-20 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2026-01-20 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2026-01-20 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2025-11-12 | Thomas Cusack | Director | A | — | — |
| 2025-11-04 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2025-11-04 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2025-11-04 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2025-10-21 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2025-10-21 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2025-10-21 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2025-10-17 | Rubric Capital Management LP | 10%+ Owner | C | — | — |
| 2025-08-12 | Adam Morgan | Director | Buy | — | — |
| 2025-08-12 | Rubric Capital Management LP | 10%+ Owner | Buy | — | — |
| 2025-08-04 | Ira Duarte | EVP, Chief Financial Officer | M | — | — |
| 2025-08-04 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| 2025-08-04 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2025-07-22 | Craig A Collard | Chief Executive Officer | M | — | — |
| 2025-07-22 | William P Forbes | EVP, Chief Development Officer | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 30,046,828 | — |
| — | Director | 8,877,027 | — |
| — | 10%+ Owner | 8,532,156 | — |
| — | Director | 5,806,751 | — |
| — | Chief Executive Officer | 856,492 | — |
| — | EVP, Chief Financial Officer | 273,531 | — |
| — | EVP, Chief Development Officer | 241,173 | — |
| — | Chief Executive Officer | 183,208 | — |
| — | Chief Operating Officer | 170,901 | — |
| — | President | 98,171 | — |
| — | Director | 87,180 | — |
| — | VP, Chief Accounting Officer | 55,374 | — |
| — | Director | 53,960 | — |
| — | Director | 53,960 | — |
| — | Director | 53,960 | — |
| — | Director | 53,960 | — |
| — | Director | 53,960 | — |
| — | Director | 52,032 | — |
| — | President & CCO | 46,648 | — |
| — | EVP, Chief Operating Officer | 33,754 | — |
| — | EVP, Drug Development | 28,330 | — |
| — | VP, Finance & CFO | 3,798 | — |
| — | SVP, Technical Operations | 2,200 | — |
| — | CFO & SVP, Finance | 1,280 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HRTX quote page; the site-wide leaderboard is on the insider transactions hub.